| [1] |
Remon J, Steuer CE, Ramalingam SS, et al. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients[J]. Ann Oncol, 2018, 29(suppl_1): i20-i27. DOI: 10.1093/annonc/mdx704.
|
| [2] |
Wang Z, Zhang X, Bai H, et al. EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer[J]. Oncology, 2012, 83(5): 248-256. DOI: 10.1159/000341381.
pmid: 22964709
|
| [3] |
Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J]. Nature, 2007, 448(7153): 561-566. DOI: 10.1038/nature05945.
|
| [4] |
Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK[J]. J Clin Oncol, 2009, 27(26): 4247-4253. DOI: 10.1200/JCO.2009.22.6993.
pmid: 19667264
|
| [5] |
Baldi L, Mengoli MC, Bisagni A, et al. Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells[J]. Lung Cancer, 2014, 86(2): 291-295. DOI: 10.1016/j.lungcan.2014.09.011.
pmid: 25312989
|
| [6] |
Popat S, Vieira de Araújo A, Min T, et al. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib[J]. J Thorac Oncol, 2011, 6(11): 1962-1963. DOI: 10.1097/JTO.0b013e31822eec5e.
pmid: 22005476
|
| [7] |
Rossing HH, Grauslund M, Urbanska EM, et al. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report[J]. BMC Res Notes, 2013, 6: 489. DOI: 10.1186/1756-0500-6-489.
pmid: 24279718
|
| [8] |
Santelmo C, Ravaioli A, Barzotti E, et al. Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib[J]. Lung Cancer, 2013, 81(2): 294-296. DOI: 10.1016/j.lungcan.2013.04.009.
pmid: 23683537
|
| [9] |
Jürgens J, Engel-Riedel W, Prickartz A, et al. Combined point mutation in KRAS or EGFR genes and EML4-ALK translocation in lung cancer patients[J]. Future Oncol, 2014, 10(4): 529-532. DOI: 10.2217/fon.13.194.
pmid: 24754584
|
| [10] |
Xu CW, Cai XY, Shao Y, et al. A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: a case report and literature review[J]. Mol Med Rep, 2015, 12(3): 4370-4375. DOI: 10.3892/mmr.2015.4001.
|
| [11] |
吴菡, 孙苏安, 刘海燕, 等. 非小细胞肺癌EGFR基因突变与EML4-ALK融合基因的表达及其临床病理特征[J]. 实用医学杂志, 2018, 34(13): 2119-2122. DOI: 10.3969/j.issn.1006-5725.2018.13.007.
|
| [12] |
Kuo YW, Wu SG, Ho CC, et al. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation[J]. J Thorac Oncol, 2010, 5(12): 2039-2040. DOI: 10.1097/JTO.0b013e3181f43274.
|
| [13] |
Shin HJ, Kho BG, Kim MS, et al. Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: case series[J]. Medicine (Baltimore), 2019, 98(9): e14699. DOI: 10.1097/MD.0000000000014699.
|
| [14] |
Yang JJ, Zhang XC, Su J, et al. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation[J]. Clin Cancer Res, 2014, 20(5): 1383-1392. DOI: 10.1158/1078-0432.CCR-13-0699.
|
| [15] |
Lee JK, Kim TM, Koh Y, et al. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation[J]. Lung Cancer, 2012, 77(2): 460-463. DOI: 10.1016/j.lungcan.2012.04.012.
pmid: 22622260
|
| [16] |
Miyanaga A, Shimizu K, Noro R, et al. Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation[J]. BMC Cancer, 2013, 13: 262. DOI: 10.1186/1471-2407-13-262.
pmid: 23714228
|
| [17] |
Tanaka H, Hayashi A, Morimoto T, et al. A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene[J]. BMC Cancer, 2012, 12: 558. DOI: 10.1186/1471-2407-12-558.
pmid: 23181703
|
| [18] |
Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer[J]. N Engl J Med, 2009, 361(10): 958-967. DOI: 10.1056/NEJMoa0904554.
|
| [19] |
Paz-Ares L, Moecks J, Klughammer B. Reply to watkins and rukazenkov (J Cell Mol Med 2010), re-letter of response to manuscript entitled ‘clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis’ (Paz-Ares et al., J Cell Mol Med, 2010, 14(1-2): 51-69)[J]. J Cell Mol Med, 2011, 15(5): 1225. DOI: 10.1111/j.1582-4934.2011.01295.x.
|
| [20] |
Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer[J]. N Engl J Med, 2014, 371(23): 2167-2177. DOI: 10.1056/NEJMoa1408440.
|
| [21] |
孔晓艳, 王明娟, 汤巧云, 等. EGFR和ALK基因异时性突变非小细胞肺癌1例报告并文献复习[J]. 中国肺癌杂志, 2024, 27(7): 559-564. DOI: 10.3779/j.issn.1009-3419.2024.106.15.
|
| [22] |
Hu Y, Xiao L, Yang N, et al. Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient[J]. Thorac Cancer, 2019, 10(5): 1252-1255. DOI: 10.1111/1759-7714.13015.
pmid: 30788907
|
| [23] |
宁婷婷, 胡钦勇, 李倩, 等. 奥希替尼与埃克替尼一线治疗EGFR阳性转移性NSCLC临床疗效观察[J]. 国际肿瘤学杂志, 2023, 50(2): 65-70. DOI: 10.3760/cma.j.cn371439-20221028-00014.
|
| [24] |
He H, Yang W, Huang Y, et al. Successful management of lung adenocarcinoma with ALK/EGFR co-alterations and PD-L1 over-expression by bevacizumab combined with chemotherapy[J]. Angiogenesis, 2022, 25(1): 5-8. DOI: 10.1007/s10456-021-09811-8.
|
)
